



POLYCYTHAEMIA VERA

RMA ID Number	Reference List for RMA147-4 as at August 2021
---------------	---

65997	Anderson DM, Keith J, Novak PD (Lexicographers) (2012). Polychromophil. Dorland's Illustrated Medical Dictionary, 32nd Edition: 1488. Elsevier Saunders, Philadelphia.
64219	Anderson LA, Duncombe AS, Hughes M, et al (2011). Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. <i>Am J Hematol</i> , 87(2): 175-82.
62343	Anderson LA, McMullin MF (2014). Epidemiology of MPN: what do we know? <i>Curr Hematol Malig Rep</i> , 9(4): 340-9.
65297	Anderson LA, Pfeiffer RM, Landgren O, et al (2009). Risk of myeloid malignancies in patients with autoimmune conditions. <i>Br J Cancer</i> , 100(5): 822-8.
5201	Ania BJ, Suman VJ, Sobell JL, et al (1994). Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. <i>Am J Hematol</i> , 47(2): 89-93.
65295	Antonioli E, Guglielmelli P, Santini V, et al (2007). Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. <i>Blood</i> , 110(13): 4620-1.
5212	Barbone E, Girolami A, Randi ML (1993). HIV infection and polycythemia vera: a relationship worth pursuing? <i>J Med</i> , 24(6): 409-11.
558	Barosi G, Baraldi A, Cazzola M, et al (1984). Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. A reorganization of erythropoiesis. <i>Scand J Haematol</i> , 32(1): 12-8.
64455	Belotti A, Doni E, Elli E, et al (2011). Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report. <i>Acta Haematol</i> , 126(1): 52-3.
17446	Belsky JL, Tachikawa K, Jablon S (1973). The health of atomic bomb survivors: a decade of examinations in a fixed population. <i>Yale J Biol Med</i> , 46(4): 284-96.
5205	Berglund S, Zettervall O (1992). Incidence of polycythemia vera in a defined population. <i>Eur J Haematol</i> , 48(1): 20-6.
5217	Berlin NI (1994). Polycythemia vera - a climatological disease. <i>Trans Am Clin Climatol Assoc</i> , 106: 25-36.
66445	Besa EC (2012). Medscape: Secondary Polycythemia. Retrieved 1 February 2013, from http://emedicine.medscape.com/article/205039-overview
66446	Besa EC (2012). Medscape: Pediatric polycythemia. Retrieved 1 February 2013, from http://emedicine.medscape.com/article/957343-overview
5204	Bilgrami S, Greenberg BR (1995). Polycythemia buba vera. <i>Semin Oncol</i> , 22(4): 307-26.
4554	Boice JD, Morin MM, Glass AG, et al (1991). Diagnostic x-ray procedures and risk of leukemia, lymphoma, and multiple myeloma. <i>JAMA</i> , 265(10): 1290-4.

5206	Bonet-Sol J, Flores-Lopez A, Caralps-Riera A (1991). Polycythaemia vera: an exceptional cause of erythrocytosis in chronic renal failure. <i>Nephron</i> , 59(2): 314.
5120	Bosch F, Cervantes F, Lopez-Guillermo A, et al (1992). Polycythaemia vera following non-Hodgkin's lymphoma. <i>Leuk Lymphoma</i> , 8(6): 501-2.
5121	Boyd MT, Maclean N, Oscier DG (1989). Detection of retrovirus in patients with myeloproliferative disease. <i>Lancet</i> , 1(8642): 814-6.
62001	Buchanich JM, Mertz KJ, Washington TL, et al (2014). Updated and expanded study of polycythemia vera and other myeloproliferative neoplasms in the tri-country area. <i>J Registry Manag</i> , 41(4): 175-81.
5122	Caldwell GG, Kelley DB, Heath CW, et al (1984). Polycythaemia vera among participants of a nuclear weapons test. <i>JAMA</i> , 252(5): 662-4.
5770	Cardis E, Gilbert ES, Carpenter L, et al (1995). Effects of low doses and low dose rates of external ionizing radiation: Cancer mortality among nuclear industry workers in three countries. <i>Radiat Res</i> , 142(2): 117-32.
5207	Carli PM (1994). Epidemiology of polycythemia vera in Cote d' Or (Burgundy). <i>Nouv Rev Fr Hematol</i> , 36(2): 147-9.
78061	Chang ET, Adami HO, Boffetta P, et al (2014). A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans. <i>Crit Rev Toxicol</i> , 44(Suppl 1): 1-81.
31373	Christensen SF, Scherber RM, Brochmann N, et al (2020). Body mass index and total symptom burden in myeloproliferative neoplasms discovery of a U-shaped association. <i>Cancers (Basel)</i> , 12(8): 2202.
17150	Clarke RH (1998). Conflicting scientific views on the health risks of low-level ionising radiation. <i>J Radio Prot</i> , 18(3): 159-60.
8791	Cordua S, Kjaer L, Skov V, et al (2019). Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. <i>Blood</i> , 134(5): 469-79.
5213	Correa PN, Eskinazi D, Axelrad AA (1994). Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. <i>Blood</i> , 83(1): 99-112.
26855	Dainiak N (2002). Hematologic consequences of exposure to ionizing radiation. <i>Exp Hematol</i> , 30(6): 513-28.
7436	Damber L, Larsson LG, Johansson L, et al (1995). A cohort study with regard to the risk of haematological malignancies in patients treated with x-rays for benign lesions in the locomotor system. I. Epidemiological analyses. <i>Acta Oncol</i> , 34(6): 713-9.
6820	Darby SC, Doll R, Gill SK, et al (1987). Long term mortality after a single treatment course with x-rays in patients treated for ankylosing spondylitis. <i>Br J Cancer</i> , 55(2): 179-90.
6753	Darby SC, Kendall GM, Fell TP, et al (1988). A summary of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes. <i>Br Med J (Clin Res Ed)</i> , 296(6618): 332-8.
7374	Darby SC, Reeves G, Key T, et al (1994). Mortality in a cohort of women given x-ray therapy for metropathia haemorrhagica. <i>Int J Cancer</i> , 56(6): 793-801.
100375	Das L, Bhansali A, Walia R (2018). Unmasking and aggravation of polycythemia vera by canagliflozin. <i>Diabet Med</i> , 35(11): 1613-6.
17085	Dayal S, Pati HP, Pande GK, et al (1997). Overt polycythemia vera after splenopneumopexy in a patient with Budd-Chiari syndrome. <i>J Clin Gastroenterol</i> , 25(2): 491-2.
38765	Descatha A, Jenabian A, Conso F, et al (2005). Occupational exposures and haematological malignancies: overview on human recent data. <i>Cancer Causes Control</i> , 16(8): 939-53.

17149	Doll R (1998). Effects of small doses of ionising radiation. <i>J Radiol Prot</i> , 18(3): 163-74.
17151	Doll R, Sharp C, Muirhead C, et al (1998). Study of UK men who had participated in the UK nuclear weapons test programme. <i>J Radiol Prot</i> , 18(3): 209-10.
17079	Doody MM, Mandel JS, Lubin JH, et al (1998). Mortality among United States radiologic technologists, 1926-90. <i>Cancer Causes Control</i> , 9(1): 67-75.
8827	Duncombe AS, Anderson LA, James G, et al (2020). Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. <i>Hemasphere</i> , 4(1): e327.
5211	Edwards TB, Nelson RP, Ballester OF, et al (1993). Polycythemia as a complication of human immunodeficiency virus infection. <i>South Med J</i> , 86(6): 686-9.
65996	Faderl S, Kantarjian HM (2010). Chronic myeloid leukemia and other myeloproliferative neoplasms. Retrieved 6 December 2012, from www.acpmedicine.com/acpmedicine/institutional/regGetFile.action?fileName=1190.pdf
65294	Fedoriw G, Dunphy CH (2011). Pathology of therapy-related myeloid neoplasms. Retrieved 23 October 2012, from http://emedicine.medscape.com/article/2026238-overview
5210	Fink L, Bauer F, Perry JJ (1993). Coincidental polycythemia vera and multiple myeloma: case report and review. <i>Am J Hematol</i> , 44(3): 196-200.
5214	Fraser P, Carpenter L, Maconochie N, et al (1993). Cancer mortality and morbidity in employees of the United Kingdom Atomic Energy Authority, 1946-86. <i>Br J Cancer</i> , 67(3): 615-24.
8802	Frenkel EP (1992). Myeloproliferative syndromes: polycythemia vera, primary (essential) thrombocythemia, and myelofibrosis. <i>Medical Oncology: Basic Principles and Clinical Management of Cancer</i> , 2nd Edition, McGraw-Hill, New York.
17163	Fujita S, Department of Statistics (1994). Estimating doses to servicemen stationed near Hiroshima. <i>RERF Update</i> , 6(2): 11.
71351	Glass DC, Schnatter AR, Tang G et al (2014). Risk of myeloproliferative disease and chronic myeloid leukemia following exposure to low-level benzene in a nested case-control study of petroleum workers. <i>Occup Environ Med</i> , 71(4): 226-74.
85806	Glass DC, Schnatter AR, Tang G, et al (2017). Exposure to benzene in a pooled analysis of petroleum industry case-control studies. <i>J Occup Environ Hyg</i> , 14(11): 863-72.
1812	Golde DW, Gulati SC (1994). The myeloproliferative diseases. <i>Harrison's Principles of Internal Medicine</i> , 13th Edition, Chapter 309: 1757-8. .
100376	Grabek J, Straube J, Bywater M, et al (2020). MPN: The molecular drivers of disease initiation, progression and transformation and their effect on treatment. <i>Cells</i> , 9(8): 1901.
17082	Green AR (1996). Pathogenesis of polycythaemia vera. <i>Lancet</i> , 347(9005): 844-5.
61606	Greil R, Pleyer L, Neureiter D, et al (2010). Chronic myeloid neoplasias and clonal overlap syndromes. <i>Epidemiology, Pathophysiology and Treatment Options</i> : 1-116. Springer Wien, New York.
17083	Grellier P, Chanson P, Casadevall N, et al (1996). Remission of polycythemia after surgical cure of acromegaly. <i>Ann Intern Med</i> , 124(5): 495-6.
17725	Gross SA, Paustenbach DJ (2018). Shanghai Health Study (2001-2009): What was learned about benzene health effects? <i>Crit Rev Toxicol</i> , 48(3): 217-51.

72440	Guidotti TL (2014). Health Risks and Occupation as a Firefighter. Medical Advisory Services, Department of Veterans' Affairs, Commonwealth of Australia.
61720	Harrison C (2010). Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. <i>Hematology Am Soc Hematol Educ Program</i> , 2010: 129-33.
17081	Harrison P, Neilson JR, Lumley MA, et al (1996). Development of polycythaemia rubra vera following treatment for centroblastic lymphoma. <i>Acta Haematol</i> , 96(2): 113-4.
38286	Harrison's 16th edition (2004). Polycythaemia vera and other myeloproliferative disorders. . Retrieved 18 November 2005, from http://www.accessmedicine.com/content.aspx?aID=65197
66448	Harrison's Internal Medicine (2012). Polycythemia vera and other myeloproliferative diseases. <i>Harrison's Internal Medicine</i> , Chapter 103.
14079	Hasselbalch HC (2015). Smoking as a contributing factor for development of polycythemia vera and related neoplasms. <i>Leuk Res</i> , S0145-2126(15): 30373-8.
100380	Hasselbalch HC (2019). Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera? <i>Haematologica</i> , 104(11): 2119-25.
16961	Hayes RB, Blair A, Stewart PA, et al (1990). Mortality of U.S. embalmers and funeral directors. <i>Am J Ind Med</i> , 18(6): 641-52.
14170	Heavner K, Gross-Davis CA, Frank AL, et al (2015). Working environment and myeloproliferative neoplasm: A population-based case-control study following a cluster investigation. <i>Am J Ind Med</i> , 58(6): 595-604.
17080	Hinshelwood S, Bench AJ, Green AR (1998). Pathogenesis of polycythaemia vera. <i>Blood Rev</i> , 11(4): 224-32.
65296	Huang LJ, Shen YM, Bulut GB (2010). Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. <i>Br J Haematol</i> , 148(6): 844-52.
5123	Ichimaru M, Ohkita T, Ishimaru T (1986). Leukemia, multiple myeloma, and malignant lymphoma. <i>Cancer in Atomic Bomb Survivors (GANN Monograph on Cancer Research)</i> , 32: 13-27. Japan Scientific Societies Press, Tokyo; Plenum Press, New York.
3087	Inskip PD, Kleinerman RA, Stovall M, et al (1993). Leukemia, lymphoma and multiple myeloma after pelvic radiotherapy for benign disease. <i>Radiat Res</i> , 135(1): 108-24.
65994	Institute of Medicine (2012). Table 7-15. Veterans and Agent Orange Update: 2010: 354-6. Washington, D.C. National Academy Press.
65995	Institute of Medicine (2012). Leukemia. Veterans and Agent Orange Update: 2010. The National Academic Press, Washington DC.
17078	Ishikawa E, Swain DL, Committee for the compilation of materials on damage caused by the atomic bombs in Hiroshima and Nagasaki (1981). The physical, medical, and social effects of the atomic bombings. <i>Injury to the human body. Hiroshima</i> , 200-03. Basic Books, New York.
8796	Jayasuriya NA, Ellervik C, Hasselbalch HC, et al (2017). Cigarette smoking, complete blood count, and myeloproliferative neoplasms--a meta-analysis. <i>Blood</i> , 130(Suppl 1): 4199.
64227	Jones AV, Cross NC (2010). [Comment] No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166. <i>Haematologica</i> , 95(7): 1226-7. Comment on ID: 64226.
17135	Kaldor J (1999). Report to the Minister assisting the Minister for Defence on recent studies of nuclear test veterans, Department of Veterans' Affairs, Canberra.

15325	Kaplan SD (1986). Update of a mortality study of workers in petroleum refineries. <i>J Occup Med</i> , 28(7): 514-6.
5124	Kilgore ES (1927). Polycythaemia in feather dyers. <i>JAMA</i> , 89(5): 342-4.
100384	Kim SY, Bae SH, Bang SM, et al (2021). The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. <i>Korean J Intern Med</i> , 36(1): 45-62.
64226	Kristinsson SY, Landgren O, Samuelsson J, et al (2010). Autoimmunity and the risk of myeloproliferative neoplasms. <i>Haematologica</i> , 95(7): 1216-20.
8760	Leal AD, Thompson CA, Wang AH, et al (2014). Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. <i>Int J Cancer</i> , 134(7): 1741-50.
8765	Leal AD, Thompson CA, Wang AH, et al (2016). Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women. <i>Cancer Epidemiol Biomarkers Prev</i> , 25(1): 151-7.
78060	Lei M, Zhang L, Lei J, et al (2015). Overview of emerging contaminants and associated human health effects. <i>Biomed Res Int</i> , 2015: 404796.
8759	Leiba A, Duek A, Afek A, et al (2017). Obesity and related risk of myeloproliferative neoplasms among Israeli adolescents. <i>Obesity (Silver Springs)</i> , 25(7): 1187-90.
20890	Lindholm Sorensen A, Hasselbalch HC (2016). Smoking and philadelphia-negative chronic myeloproliferative neoplasms. <i>Eur J Haematol</i> , 97(1): 63-9.
45580	Lowenthal RM, Tuck DM, Bray IC (2007). Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative disorders: a case-control study. <i>Intern Med J</i> , 37(9): 614-9.
100388	Marchetti M, Carobbio A, Capitoni E, et al (2018). Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. <i>Am J Hematol</i> , 93(5): 698-703.
5125	Marsh GM, Enterline PE, McCraw D (1991). Mortality patterns among petroleum refinery and chemical plant workers. <i>Am J Ind Med</i> , 19(1): 29-42.
14267	McMullin MF, Anderson LA (2020). Aetiology of myeloproliferative neoplasms. <i>Cancers (Basel)</i> , 12(7): 1810.
100390	McMullin MF, Harrison CN, Ali S, et al (2019). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. <i>Br J Haematol</i> , 184(2): 176-91.
554	Mellemkjoer L, Olsen JH, Linet MS, et al (1995). Cancer risk after splenectomy. <i>Cancer</i> , 75(2): 577-83.
8803	Mettler FA, Upton AC (1995). <i>Medical Effects of Ionizing Radiation</i> , 2nd Edition, 121-2. WB Saunders Company, Philadelphia.
3040	Michalek JE, Wolfe WH, Miner JC (1990). Health status of air force veterans occupationally exposed to herbicides in Vietnam. <i>JAMA</i> , 264(14): 1832-6.
5126	Modan B, Kallner H, Zemer D, et al (1971). A Note on the increased risk of polycythaemia vera in Jews. <i>Blood</i> , 37(2): 172-6.
17122	Mossman KL (1998). The linear no-threshold debate: where do we go from here? <i>Med Phys</i> , 25(3): 279-84.
17201	Muirhead CR, Goodill AA, Haylock RG, et al (1999). Occupational radiation exposure and mortality: second analysis of the National Registry for radiation workers. <i>J Radiol Prot</i> , 19(1): 3-26.
72652	Murphy F, Kroll ME, Pirie K et al (2013). Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. <i>Br J Cancer</i> , 108(11): 2390-8.
5203	Murphy S (1992). Polycythemia vera. <i>Disease-a-Month</i> , 38(3): 164-212.

17148	Najean Y, Rain JD, Billotey C (1998). Epidemiological data in polycythaemia vera: a study of 842 cases. <i>Hematol Cell Ther</i> , 40(4): 159-65.
90277	National Academies of Sciences, Engineering, and Medicine (2018). <i>Veterans and Agent Orange: Update 11</i> . National Academy of Sciences, Washington, D.C. National Academy Press.
17121	Nussbaum RH (1998). The linear no-threshold dose-effect relation: is it relevant to radiation protection regulation? <i>Med Phys</i> , 25(3): 291-9.
14173	O'Sullivan J, Mead AJ (2019). Heterogeneity in myeloproliferative neoplasms. <i>Adv Biol Regul</i> , 71: 55-68.
5208	Parkes G (1985). Polycythemia and nuclear 'exposure'. <i>JAMA</i> , 253(10): 1391.
91038	Pedersen KM, Bak M, Sorensen AL, et al (2018). Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. <i>Cancer Med</i> , 7(11): 5796-802.
14169	Podoltsev NA, Wang X, Wang R, et al (2020). Diet and risk of myeloproliferative neoplasms in older individuals from the NIH-AARP cohort. <i>Cancer Epidemiol Biomarkers Prev</i> , 29(11): 2343-50.
16992	Pollycove M (1998). Nonlinearity of radiation health effects. <i>Environ Health Perspect</i> , 106(Suppl 1): 363-8.
17147	Pollycove M, Feinendegen LE (1999). Molecular biology, epidemiology, and the demise of the linear no-threshold (LNT) hypothesis. <i>C R Acad Sci III</i> , 322(2-3): 197-204.
8790	Poluben L, Puligandla M, Neuberg D, et al (2019). Genomic characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. <i>Am J Hematol</i> , 94(1): 62-73.
5202	Prchal JT, Prchal JF (1994). Evolving understanding of the cellular defect in polycythemia vera: implications for its clinical diagnosis and molecular pathophysiology. <i>Blood</i> , 83(1): 1-4.
66447	Prchal JT, Samuelson S (2009). Polycythemia vera. Retrieved 1 February 2013, from http://www.merckmanuals.com/professional/print/hematology_and_oncology/myeloproliferative_disorders/polycythemia_vera.html
3046	Preston DL, Kusumi S, Tomonaga M, et al (1994). Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. <i>Radiat Res</i> , 137(2 Suppl): S68-97. Erratum <i>Radiat Res</i> , 139(1): 129.
5215	Prochazka AV, Markowe HLJ (1986). The epidemiology of polycythaemia vera in England and Wales 1968-1982. <i>Br J Cancer</i> , 53(1): 59-64.
14202	Pulte D (2016). Determining the role of smoking in myeloproliferative neoplasms: is it a matter of picking the right control group? <i>Eur J Haematol</i> , 97(1): 3-4.
64537	Quirk P, Weinerman BH (1980). Polycythemia vera after chemotherapy-induced remission of Hodgkin's disease: report of a case. <i>Can Med Assoc J</i> , 122(12): 1399-400.
3296	Quitt M, Cassel A, Yoffe A, et al (2004). Autonomous growth of committed hematopoietic progenitors from peripheral blood of workers exposed to low levels of benzene. <i>J Occup Environ Med</i> , 46(1): 27-9.
31087	Ramanathan G, Hoover BM, Fleischman AG (2020). Impact of host, lifestyle and environmental factors in the pathogenesis of MPN. <i>Cancers (Basel)</i> , 12(8): 2038.
5127	Ratnoff, WD, Gress RE (1980). The familial occurrence of polycythemia vera: report of a father and son, with consideration of the possible etiologic role of exposure to organic solvents, including tetrachloroethylene. <i>Blood</i> , 56(2): 233-6.

100408	Roaldsnes C, Holst R, Frederiksen H, et al (2017). Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. <i>Eur J Haematol</i> , 98(1): 85-93. [Abstract]
8807	Roff SR (1997). Increased mortality in US nuclear test veterans. <i>Lancet</i> , 349(9044): 64.
100409	Rumi E, Barate C, Benevolo G, et al (2020). Myeloproliferative and lymphoproliferative disorders: State of the art. <i>Hematol Oncol</i> , 38(2): 121-8. [Abstract]
32800	Rumi E, Cazzola M (2017). Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. <i>Blood</i> , 129(6): 680-92.
68379	Schnatter AR, Glass DC, Tang G, et al (2012). Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. <i>J Natl Cancer Inst</i> , 104(22): 1724-37.
64454	Seaman V, Dearwent SM, Gable D, et al (2010). A multidisciplinary investigation of a polycythemia vera cancer cluster of unknown origin. <i>Int J Environ Res Public Health</i> , 7(3): 1139-52.
64453	Seaman V, Jumaan A, Yanni E, et al (2009). Use of molecular testing to identify a cluster of patients with polycythemia vera in Eastern Pennsylvania. <i>Cancer Epidemiol Biomarkers Prev</i> , 18(2): 534-40.
8792	Shallis RM, Wang R, Davidoff A, et al (2020). Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Rev</i> , 42: 100706.
5216	Shimizu Y, Kato H, Schull WJ (1990). Studies of the mortality of A-Bomb survivors. 9. Mortality, 1950-85: Part 2. Cancer mortality based on the recent revised doses (DS86). <i>Radiat Res</i> , 121(2): 120-41.
17120	Sinclair WK (1998). The linear no-threshold response: why not linearity? <i>Med Phys</i> , 25(3): 285-90.
6419	Smith PG, Doll R (1981). Mortality from cancer and all causes among British radiologists. <i>Br J Radiol</i> , 54(639): 187-94.
769	Smith PG, Doll R (1982). Mortality among patients with ankylosing spondylitis after a single treatment course with x-rays. <i>Br Med J (Clin Res Ed)</i> , 284(6314): 449-60.
5209	Sobell JL, Codd MB, Silverstein MN, et al (1987). Polycythemia vera among participants of a nuclear weapons test. <i>JAMA</i> , 257(9): 1178-9.
14165	Spivak JL (2017). Myeloproliferative neoplasms. <i>N Engl J Med</i> , 376(22): 2168-81.
5128	Stavropoulos C, Petropoulou F, Christophoraki M, et al (1991). Frequency of HLA-A, B and DR antigens in patients with polycythemia vera. <i>Acta Haematol</i> , 86(1): 51-2.
61592	Stein BL, Moliterno AR (2010). Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. <i>JAMA</i> , 303(24): 2513-8.
74959	Stenehjem JS, Kjaerheim K, Bratveit M, et al (2015). Benzene exposure and risk of lymphohaematopoietic cancers in 25 000 offshore oil industry workers. <i>Br J Cancer</i> , 112(9): 1603-12.
64225	Stuart BJ, Viera AJ (2004). Polycythemia vera. <i>Am Fam Physician</i> , 69(9): 2139-44.
64456	Sutherland ND, Gonzalez-Peralta R, Douglas-Nikitin V, et al (2004). Polycythemia vera in a child following treatment for acute lymphoblastic leukemia. <i>J Pediatr Hematol Oncol</i> , 26(5): 315-9.
557	Swerdlow AJ, Douglas AJ, Hudson GV, et al (1993). Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. <i>Br J Cancer</i> , 68(5): 1006-11.
17084	Tefferi A (1999). Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic

	myeloid metaplasia, and chronic myelogenous leukemia. <i>Semin Hematol</i> , 36(1 Suppl 2): 3-8.
61596	Tefferi A (2010). Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. <i>Leukemia</i> , 24(6): 1128-38.
64216	Tefferi A (2012). Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. <i>Am J Hematol</i> , 87(3): 285-93.
100404	Tefferi A (2016). Myeloproliferative neoplasms: A decade of discoveries and treatment advances. <i>Am J Hematol</i> , 91(1): 50-8.
100402	Tefferi A (2019). Overview of the myeloproliferative neoplasms. Retrieved 12 July 2021, from https://www.uptodate.com/contents/overview-of-the-myeloproliferative-neoplasms
100400	Tefferi A (2020). Clinical manifestations and diagnosis of polycythemia vera. Retrieved 12 July 2021, from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-polycythemia-vera
100383	Tefferi A (2021). Prognosis and treatment of polycythemia vera. Retrieved 12 July 2021, from https://www.uptodate.com/contents/prognosis-and-treatment-of-polycythemia-vera
8763	Tefferi A, Pardanani A (2019). Essential thrombocythemia. <i>N Engl J Med</i> , 381(22): 2135-44.
17241	The committee for the compilation of material on damage caused by the atomic bombs in Hiroshima and Nagasaki (1981). Hiroshima and Nagasaki: the physical, medical and social effects of the atomic bombings. Chapter 5 Radiation from the atomic bomb and Chapter 9 Aftereffects and genetic effects. 67-79 & 200-1.
8794	Titmarsh GJ, Duncombe AS, McMullin MF, et al (2014). How common are myeloproliferative neoplasms? A systematic review and meta-analysis. <i>Am J Hematol</i> , 89(6): 581-7.
6905	Travis LB, Weeks J, Curtis RE, et al (1996). Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. <i>J Clin Oncol</i> , 14(2): 565-71.
556	Tura S, Fiacchini M, Zinzanni PL, et al (1993). Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. <i>J Clin Oncol</i> , 11(5): 925-30.
64478	United Nations Scientific Committee on the Effects of Atomic Radiation (2008). Sources and effects of ionizing radiation. UNSCEAR 2008 Report to the General Assembly with Scientific Annexes, Vol II Annex D: 151-89. United Nations, New York.
60230	UNSCEAR (2008). Effects of Ionizing Radiation. UNSCEAR 2006 Report. United Nations Scientific Committee on the Effects of Atomic Radiation, Volume 1: 101. United Nations Publication.
64373	Vainchenker W, Delhommeau F, Constantinescu SN, et al (2011). New mutations and pathogenesis of myeloproliferative neoplasms. <i>Blood</i> , 118(7): 1723-35.
7534	Valentine WN, Beck WS, Follette JH, et al (1952). Biochemical studies in chronic myelocytic leukemia, polycythemia vera and other idiopathic myeloproliferative disorders. <i>Blood</i> , 7(10): 959-77.
64269	Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. <i>Blood</i> , 114(5): 937-51.
67411	Vassiliou GS, Green AR (2007). Polycythaemia, essential thrombocythaemia and myelofibrosis. <i>ABC of Clinical Haematology</i> , 3rd Edition, Chapter 4: 17-21. Blackwell Publishing.

5218	Venegoni P, Cyprus G (1994). Polycythemia and the heart. A review. <i>Tex Heart Inst J</i> , 21(3): 198-201.
100407	Verma SP, Singh B, Kushwaha R, et al (2020). Polycythaemia following treatment of lymphoplasmacytic lymphoma. <i>BMJ Case Rep</i> , 13(10): e235687.
7499	Watanabe KK, Kang HK, Dalager NA (1995). Cancer mortality risk among military participants of a 1958 atmospheric nuclear weapons test. <i>Am J Public Health</i> , 85(4): 523-7.
64218	Weinberg I, Borohovitz A, Krichevsky S, et al (2011). Janus Kinase V617F mutation in cigarette smokers. <i>Am J Hematol</i> , 87(1): 5-8.
5129	Weinberg JB (1989). Sequential development of polycythaemia vera and chronic myelocytic leukaemia in a patient following radiation exposure from nuclear weapons tests. <i>Am J Med</i> , 87(1): 121-3.
13870	Weiss HA, Darby SC, Fearn T, et al (1995). Leukemia mortality after X-Ray treatment for ankylosing spondylitis. <i>Radiat Res</i> , 142: 1-11.
7373	Weiss HA, Darby SC, Doll R (1994). Cancer mortality following x-ray treatment for ankylosing spondylitis. <i>Int J Cancer</i> , 59(3): 327-38.
91051	WHO (World Health Organization) (2018). Benzene. IARC Monographs, Vol 120. International Agency for Research on Cancer World Health Organization.